Third, while ITRI-ES pharmacological properties have been described in glaucoma models (showing intraocular bioavailability up to 24 h and selective ROCK1/2-MYLK4 inhibition) [27,28], its pharmacokinetics in NMOSD optic neuritis remain untested. This evidence concerns the gene MYLK4 and optic neuritis.